JP2023030022A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023030022A5 JP2023030022A5 JP2022199857A JP2022199857A JP2023030022A5 JP 2023030022 A5 JP2023030022 A5 JP 2023030022A5 JP 2022199857 A JP2022199857 A JP 2022199857A JP 2022199857 A JP2022199857 A JP 2022199857A JP 2023030022 A5 JP2023030022 A5 JP 2023030022A5
- Authority
- JP
- Japan
- Prior art keywords
- fibrosis
- pharmaceutical composition
- irap
- composition according
- inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2015903035 | 2015-07-30 | ||
| AU2015903035A AU2015903035A0 (en) | 2015-07-30 | Fibrotic treatment | |
| JP2020127888A JP7457360B2 (ja) | 2015-07-30 | 2020-07-29 | 線維症の処置 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020127888A Division JP7457360B2 (ja) | 2015-07-30 | 2020-07-29 | 線維症の処置 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023030022A JP2023030022A (ja) | 2023-03-07 |
| JP2023030022A5 true JP2023030022A5 (https=) | 2023-09-29 |
Family
ID=57883919
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018504650A Withdrawn JP2018527330A (ja) | 2015-07-30 | 2016-07-29 | 線維症の処置 |
| JP2020127888A Active JP7457360B2 (ja) | 2015-07-30 | 2020-07-29 | 線維症の処置 |
| JP2022199857A Pending JP2023030022A (ja) | 2015-07-30 | 2022-12-15 | 線維症の処置 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018504650A Withdrawn JP2018527330A (ja) | 2015-07-30 | 2016-07-29 | 線維症の処置 |
| JP2020127888A Active JP7457360B2 (ja) | 2015-07-30 | 2020-07-29 | 線維症の処置 |
Country Status (8)
| Country | Link |
|---|---|
| US (5) | US10100311B2 (https=) |
| EP (1) | EP3328384B1 (https=) |
| JP (3) | JP2018527330A (https=) |
| AU (1) | AU2016301113B2 (https=) |
| CA (1) | CA3017028C (https=) |
| HK (1) | HK1256423A1 (https=) |
| SG (1) | SG11201808478RA (https=) |
| WO (1) | WO2017015720A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3294721A4 (en) * | 2015-05-08 | 2018-11-07 | Monash University | 4h-pyran compounds as insulin-regulated aminopeptidase (irap) inhibitors |
| JP2018527330A (ja) | 2015-07-30 | 2018-09-20 | モナシュ ユニバーシティー | 線維症の処置 |
| WO2019014710A1 (en) * | 2017-07-17 | 2019-01-24 | Monash University | ANGIOTENSIN RECEPTOR AGONISTS AND USES THEREOF |
| EP3902460A4 (en) * | 2018-12-28 | 2023-01-11 | The General Hospital Corporation | ANTI-EPHRIN B2 BLOCKER ANTIBODIES FOR THE TREATMENT OF FIBROTIC DISEASES |
| WO2021050089A1 (en) * | 2019-09-09 | 2021-03-18 | Washington State University | Genetic test for identifying cats at a high risk for developing tubulointerstitial fibrosis |
| CA3171882A1 (en) | 2020-02-19 | 2021-08-26 | Hepion Pharmaceuticals, Inc. | Use of cyclosporine analogues for treating fibrosis |
| WO2023099589A1 (en) * | 2021-12-01 | 2023-06-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Irap inhibitors for use in the treatment of inflammatory diseases |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2403340T3 (es) * | 2004-09-09 | 2013-05-17 | Howard Florey Institute Of Experimental Physiology And Medicine | Inhibidores de aminopeptidasa regulada por insulina (IRAP) y usos de los mismos |
| WO2007024946A2 (en) * | 2005-08-23 | 2007-03-01 | Wyeth | Methods for the treatment of anxiety and for identification of anxiolytic agents |
| EP2262797A4 (en) * | 2007-11-19 | 2011-11-30 | Howard Florey Inst | INHIBITORS OF INSULIN REGULATED AMINO PEPTIDASE (IRAP) AND APPLICATIONS THEREOF |
| CN104302305A (zh) * | 2011-12-16 | 2015-01-21 | 塔瑞克斯制药有限公司 | 用于治疗纤维化的血管紧张素 |
| KR20140127307A (ko) | 2012-02-06 | 2014-11-03 | 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 | 섬유성 질병을 치료하기 위한 pi3k 억제제 |
| JP6327923B2 (ja) | 2014-04-25 | 2018-05-23 | 旭化成株式会社 | ポリアセタール樹脂組成物、及びそれからなる成形体 |
| DE102014114090A1 (de) | 2014-09-29 | 2016-03-31 | Karlsruher Institut für Technologie | Verfahren zur Abtrennung von Aluminium bei der Calciumsilikatproduktion |
| US9519061B2 (en) * | 2014-12-26 | 2016-12-13 | Here Global B.V. | Geometric fingerprinting for localization of a device |
| EP3294721A4 (en) * | 2015-05-08 | 2018-11-07 | Monash University | 4h-pyran compounds as insulin-regulated aminopeptidase (irap) inhibitors |
| JP2018527330A (ja) * | 2015-07-30 | 2018-09-20 | モナシュ ユニバーシティー | 線維症の処置 |
-
2016
- 2016-07-29 JP JP2018504650A patent/JP2018527330A/ja not_active Withdrawn
- 2016-07-29 EP EP16829507.9A patent/EP3328384B1/en active Active
- 2016-07-29 AU AU2016301113A patent/AU2016301113B2/en active Active
- 2016-07-29 US US15/747,697 patent/US10100311B2/en active Active
- 2016-07-29 CA CA3017028A patent/CA3017028C/en active Active
- 2016-07-29 SG SG11201808478RA patent/SG11201808478RA/en unknown
- 2016-07-29 HK HK18115556.4A patent/HK1256423A1/zh unknown
- 2016-07-29 WO PCT/AU2016/050681 patent/WO2017015720A1/en not_active Ceased
-
2018
- 2018-09-06 US US16/123,898 patent/US10787668B2/en active Active
-
2020
- 2020-07-29 JP JP2020127888A patent/JP7457360B2/ja active Active
- 2020-08-04 US US16/984,996 patent/US11078488B2/en active Active
-
2021
- 2021-07-01 US US17/365,260 patent/US11834663B2/en active Active
-
2022
- 2022-12-15 JP JP2022199857A patent/JP2023030022A/ja active Pending
-
2023
- 2023-10-26 US US18/495,512 patent/US20240084308A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023030022A5 (https=) | ||
| Wang et al. | Quercetin dihydrate inhibition of cardiac fibrosis induced by angiotensin II in vivo and in vitro | |
| Raines | The extracellular matrix can regulate vascular cell migration, proliferation, and survival: relationships to vascular disease | |
| JP2020189845A5 (https=) | ||
| AU2002328494B2 (en) | Drugs containing chymase inhibitor and ACE inhibitor as the active ingredients | |
| AU2016227486A1 (en) | Angiotensin ll receptor agonist for treating pulmonary fibrosis | |
| CA2358400A1 (en) | Methods for treating conditions associated with the accumulation of excess extracellular matrix | |
| BR122018015003B1 (pt) | kit compreendendo composições farmacêuticas de inibidor da nep e de valsartan ou seus sais | |
| JP2001502292A (ja) | Ｐｄｇｆアンタゴニストとしての４−〔２−（ｎ−２−カルボキサミドインドール）アミノエチル〕ベンゼンスルホンアミドまたはスルホニル尿素 | |
| Dell’Aica et al. | Hyperforin blocks neutrophil activation of matrix metalloproteinase-9, motility and recruitment, and restrains inflammation-triggered angiogenesis and lung fibrosis | |
| JP2018527330A5 (https=) | ||
| Tan et al. | Tryptase promotes the profibrotic phenotype transfer of atrial fibroblasts by PAR2 and PPARγ pathway | |
| JP2009504737A (ja) | 脈管疾患の治療又は予防のためのｐａｒ−１／ｐａｒ−４阻害剤の使用 | |
| US20160175286A1 (en) | Selective at2 receptor agonists for use in treatment of cachexia | |
| JP2009535330A5 (https=) | ||
| WO2019010482A1 (en) | COMPOSITIONS AND METHODS FOR MODULATING COLUMN MATURATION | |
| JP2002506881A (ja) | 新規マトリックスメタロプロテイナーゼ阻害剤および下方調節剤 | |
| US11505582B2 (en) | CCN3 and CCN3 peptides and analogs thereof for therapeutic use | |
| Andersson et al. | Fatal acute pancreatitis: Characteristics of patients never reaching hospital | |
| Paccosi et al. | The monocyte chemotactic protein synthesis inhibitor bindarit prevents mesangial cell proliferation and extracellular matrix remodeling | |
| AU2013202269A1 (en) | Compositions and methods for the treatment of fibrosis and fibrotic diseases | |
| Koshy et al. | Collagen cross-linking: new dimension to cardiac remodeling | |
| Shi et al. | Apixaban attenuates ischemia-induced myocardial fibrosis by inhibition of Gq/PKC signaling | |
| IL293894A (en) | Combination treatment of liver diseases using integrin inhibitors | |
| See et al. | Fibrosis as a therapeutic target post-myocardial infarction |